source
- BlossomHill Therapeutics targets $112 million IPO to fund EGFR lung-cancer drug BH-30643BlossomHill Therapeutics, a San Diego oncology biotech, announced plans for an initial public offering to raise about $112 million. The company intends to sell 7.8 million shares at $15-$17 each,…
- Biologics surge drives CMOs and CDMOs to boost sterile fill-finish and prefilled syringe capacityBiologics, biosimilars and GLP-1 therapies are increasing demand for sterile injectable products, prompting contract manufacturers to expand capacity. CMOs and CDMOs are adding fill-finish, lyophi…